Le Lézard
Classified in: Health, Business, Covid-19 virus
Subjects: CCA, FVT

Aflac Incorporated to Release Fourth Quarter Results on February 2, 2022


COLUMBUS, Ga., Jan. 13, 2022 /PRNewswire/ -- Aflac Incorporated (NYSE: AFL) announced today that it will release fourth quarter financial results after the market closes on February 2, 2022. At that time, earnings materials, including the fourth quarter 2021 earnings release and Financial Analysts Briefing supplement, will be available on the company's Investor Relations website, investors.aflac.com.

In conjunction with the earnings release, Aflac Incorporated will webcast a conference call scheduled for 8:00 a.m. (ET) on Thursday, February 3, 2022. During the webcast, Aflac Incorporated Chairman and Chief Executive Officer Daniel P. Amos, President and Chief Operating Officer of Aflac Incorporated Frederick J. Crawford and Executive Vice President and Chief Financial Officer of Aflac Incorporated Max K. Brodén will discuss the company's fourth quarter results and outlook, including with regard to the ongoing COVID-19 pandemic. Other members of executive management from the U.S. and Japan will also be available to answer questions during the webcast. To listen to the conference call, please register at investors.aflac.com five to seven minutes prior to the scheduled start time. 

About Aflac Incorporated
Aflac Incorporated (NYSE: AFL) is a Fortune 500 company helping provide protection to more than 50 million people through its subsidiaries in Japan and the U.S., where it is a leading supplemental insurer by paying cash fast when policyholders get sick or injured. For more than six decades, insurance policies of Aflac Incorporated's subsidiaries have given policyholders the opportunity to focus on recovery, not financial stress. In the U.S., Aflac is the number one provider of voluntary/worksite insurance products. Aflac Life Insurance Japan is the leading provider of medical and cancer insurance in Japan, where it insures 1 in 4 households. In 2021, Aflac Incorporated was proud to be included as one of the World's Most Ethical Companies by Ethisphere for the 15th consecutive year, Fortune's list of World's Most Admired Companies for the 20th time, Bloomberg's Gender-Equality Index for the second consecutive year, and in the Dow Jones Sustainability North America Index. In 2021, Aflac Incorporated also became a signatory of the Principles for Responsible Investment (PRI). To find out how to get help with expenses health insurance doesn't cover, get to know us at aflac.com or aflac.com/espanol. Investors may learn more about Aflac Incorporated and its commitment to ESG and social responsibility at investors.aflac.com under "Sustainability."

(PRNewsfoto/Aflac Incorporated)

Analyst and investor contact ? David A. Young, 706.596.3264 or 800.235.2667, or [email protected]

Media contact ? Ines Gutzmer, 762.207.7601 or [email protected]

SOURCE Aflac Incorporated


These press releases may also interest you

at 10:19
Revvity's EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits...

at 10:17
Fx Chocolate®, a Designs for Health brand that provides functional amounts of high-quality supplements in handcrafted chocolate, today announced the launch of its Yes Whey!!!tm chocolate supplement bar. Yes Whey!!!tm harnesses 15 grams of...

at 10:16
Varian, a Siemens Healthineers Company, announces its collaboration with BaraSeen Medical Company to introduce the first Halcyon system in Saudi Arabia - with its hallmark sustainability features - at BaraSeen's initial specialized standalone Batik-X...

at 10:15
From the childhood dream of becoming a veterinarian and saving the lives of pets, to today's realities of practicing veterinary medicine, the deep commitment veterinarians feel for their calling remains unchanged. However, certain factors make that...

at 10:12
Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical...

at 10:02
Boston Institute of Biotechnology, LLC (BIB) in collaboration with BIBo-Biopharma, proudly announces the successful completion of a groundbreaking 30,000L fermentation run, marking a significant milestone in biotechnology history....



News published on and distributed by: